Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

NCT03249714 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Ofatumumab
DRUG: Matching placebo of ofatumumab

Sponsor

Novartis Pharmaceuticals